Letter: the ethics of using inferior regimens in H. pylori randomised trials

Comment

D Y Graham et al. Aliment Pharmacol Ther. 2012 Apr.

. 2012 Apr;35(7):852-4; discussion 858.

doi: 10.1111/j.1365-2036.2011.04944.x.

No abstract available

Comment in

Letter: the ethics of using inferior regimens in H. pylori randomised trials - invited comment.
O'Connor JP, O'Morain CA. O'Connor JP, et al. Aliment Pharmacol Ther. 2012 Apr;35(7):854-6; discussion 858. doi: 10.1111/j.1365-2036.2011.04951.x. Aliment Pharmacol Ther. 2012. PMID: 22404412 No abstract available.
Letter: the ethics of using inferior regimens in H. pylori randomised trials - invited comment.
Gisbert JP. Gisbert JP. Aliment Pharmacol Ther. 2012 Apr;35(7):856-7; discussion 858. doi: 10.1111/j.1365-2036.2011.04985.x. Aliment Pharmacol Ther. 2012. PMID: 22404413 No abstract available.

Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG, Kim KH, Kim HY, Baik GH. Kim YS, et al. Aliment Pharmacol Ther. 2011 Nov;34(9):1098-105. doi: 10.1111/j.1365-2036.2011.04843.x. Epub 2011 Sep 19. Aliment Pharmacol Ther. 2011. PMID: 21923713 Clinical Trial.